References
- 1. Geffken GR, Ward HE, Staab JP, Carmichael SL, Evans DL. Psychiatric morbidity in endocrine disorders. Psychiatr Clin North Am. 1998; 21:473-89.10.1016/S0193-953X(05)70017-4
- 2. Kathol RG, Delahunt JW. The relationship of anxiety and depression to symptoms of hyperthyroidism using operational criteria. Gen Hosp Psychiatry. 1986; 8:23-8.10.1016/0163-8343(86)90060-5
- 3. Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J. A psychiatric and neuropsychological study of patients with untreated Grave’s disease. Gen Hosp Psychiatry. 1988; 10:49-55.10.1016/0163-8343(88)90084-9
- 4. Fahrenfort JJ, Wilterdink AM, van der Veen EA. Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology. 2000; 25:201-11.10.1016/S0306-4530(99)00050-5
- 5. Scheffer C, Heckmann C, Mijic T, Rudorff KH. Chronic distress syndrome in patients with Graves’ disease. Med Klin. 2004; 99:578-84.10.1007/s00063-004-1089-3
- 6. Elberling TV, Rasmussen AK, Feldt-Rasmussen U, Hording M, Perrild H, Waldemar G. Impaired healthrelated quality of life in Graves’ disease. A prospective study. Eur J Endocrinol. 2004; 151:549-55.10.1530/eje.0.1510549
- 7. Bianchi GP, Zaccheroni V, Solaroli E, Vescini F, Cerutti R, Zoli M, et al. Health-related quality of life in patients with thyroid disorders. Qual Life Res. 2004; 13:45-54.10.1023/B:QURE.0000015315.35184.66
- 8. Gulseren S, Gulseren L, Hekimsoy Z, Cetinay P, Ozen C, Tokatlioglu B. Depression, anxiety, healthrelated quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res. 2006; 37:133-9.10.1016/j.arcmed.2005.05.008
- 9. Razvi S, Ingoc IE, McMillan CV, Weaver JU. Health status in patients with sub-clinical hypothyroidism. Eur J Endocrinol. 2005; 152:713-17.10.1530/eje.1.01907
- 10. Li L, Wang HM, Shen Y. Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalization. J Epidemiol Community Health. 2003; 57:259-63.10.1136/jech.57.4.259
- 11. Hemingway H, Stafford M, Stansfeld S, Shipley M, Marmot M. Is the SF-36 a valid measure of change in population health? Results from Whitehall II study. BMJ. 1997; 315:1273-9.10.1136/bmj.315.7118.1273
- 12. Hemingway H, Nicholson A, Stafford M, Roberts R, Marmot M. The impact of socioeconomic status on health functioning as assessed by the SF-36 questionnaire: the Whitehall II study. Am J Public Health. 1997; 87:1484-90.10.2105/AJPH.87.9.1484
- 13. McHorney CA, Ware JE, Rachel Lu JF, Sherbourne CD. The MOS 36-item Short-form Health Survey (SF-36): III. Test of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994; 32:40-6610.1097/00005650-199401000-00004
- 14. Jolliffe IT. Principal Component Analysis. New York: Springer; 1986. p. 62-70.
- 15. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis. 1987; 40:171-8.10.1016/0021-9681(87)90069-5
- 16. Ware JE, Gandek B. IQOLA Project Group. The SF-36 Health Survey: Development and use in mental health research and the IQOLA Project. Int J Ment Health. 1994; 23:49-73.10.1080/00207411.1994.11449283
- 17. Hobson P, Bhowmick B, Meara J. Use of the SF-36 questionnaire in cerebrovascular disease. Stroke. 1997; 28:464-5.
- 18. Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, et al. The development and validation of a dysphasia-specific quality-of-life questionnaire for patients with head and neck cancer. The Anderson dysphasia inventory. Arch Otolaryngol Head Neck Surg. 2001; 127:870-6.
- 19. Jenkinson C, Coulter A, Wright L. Short form 36 (SF-36) health survey questionnaire: Normative data for adults of working age. Br Med J. 1993; 306:1437-40.10.1136/bmj.306.6890.1437
- 20. Ware JE, Sherbourne CD. The MOS 36 item short form health survey (SF-36). Med Care. 1992; 30:473-83.10.1097/00005650-199206000-00002
- 21. Pinar R. Reliability and construct validity of the SF-36 in Turkish cancer patients. Qual Life Re. 2005; 14:259-64.
- 22. Failde I, Ramos I. Validity and reliability of the SF-36 Health Survey Questionnaire in patients with coronary artery disease. J Clin Epidemiol. 2000; 53:359-65.10.1016/S0895-4356(99)00175-4
- 23. Koh ET, Leong KP, Tsou IY, Lim VH, Pong LY, Chong SY, et al. The reliability, validity and sensitivity of the Chinese version of SF-36 in oriental patients with rheumatoid arthritis. Rheumatology. 2006; 45:1023-8.10.1093/rheumatology/kel051
- 24. Riley ED, Bangsberg DR, Perry S, Clark RA, Moss AR, Wu AW. Reliability and validity of the SF-36 in HIV-infected homeless and marginally housed individuals. Qual Life Res. 2003; 12:1051-8.10.1023/A:1026166021386
- 25. van der Heijden PG, van Buuren S, Fekkes M, Radder J, Verrips E. Unidimensionality and reliability under Mokken scaling of the Dutch language version of the SF-36. Qual Life Res. 2003; 12:189-98.
- 26. Jenkinson C, Peto V, Coulter A. Making sense of ambiguity: evaluation in internal reliability and face validity of the SF-36 questionnaire in women presenting with menorrhagia. Qual Health Care. 1996; 5:9-12.10.1136/qshc.5.1.9
- 27. Bunevicius R, Velickiene D, Prange AJ Jr. Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves’ disease. Gen Hosp Psychiatry. 2005; 27:133-9.10.1016/j.genhosppsych.2004.10.002
- 28. Liu J, Shu Q, Wang JZ. Assessing the quality of life of patients with systemic lupus erythematosus using SF-36. Chin J Public Health (Chin). 2004; 11:1383-4.
- 29. McHorney CA, Ware JE, Raczek AE. The MOS 36-items Short-form Health Survey (SF-36) II. Psychometric and clinical test of validity in measuringphysical and mental health constructs. Med Care. 1993; 31:247-63.10.1097/00005650-199303000-00006
- 30. Ruta DA, Hurst NP, Kind P, Hunter M, Stubings A. Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br J Rheumatol. 1998; 37:425-36.10.1093/rheumatology/37.4.425
- 31. Abraham-Nordling M, Wallin G, Lundell G, Törring O. Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves’ disease. Eur J Endocrinol. 2007; 2:173-9.10.1530/eje.1.02336
- 32. Abraham-Nordling M, Törring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, Wallin G. Graves’ disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid. 2005; 11:1279-86.10.1089/thy.2005.15.1279
- 33. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol. 2005; 152:1-9. 10.1530/eje.1.01809